New Pediatric Dosing for Aptivus, Patients 2-18 Years, New Oral Solution and Info on Coadministration With Midazolam
June 23, 2008
On June 23, 2008, FDA approved a new Aptivus (tipranavir) oral solution (100 mg/mL). The product label has been updated to include dosing recommendations for pediatric patients 2-18 years of age.
In addition, information regarding oral and parenterally administered midazolam was updated in the Contraindication and Drug Interactions section.
Please see the attached pdf file for specific pediatric labeling information and for updated information about midazolam.
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.